Drug Resistance Pattern of Salmonella Typhi in Patients Suffering from Enteric Fever - Experience from Tertiary Care Hospital of Peshawar.
DOI:
https://doi.org/10.52206/jsmc.2023.13.4.825Abstract
Background: Enteric fever is one of the most common infections in Southeast Asia. Over the last decade, increasing drug resistance against salmonella has been documented.
Objectives: This study aimed to determine the drug resistance pattern of salmonella typhi at a tertiary care hospital in Peshawar.
Material and Methods: A cross-sectional observational study was conducted at Rehman Medical Institute, Peshawar over one year, from June 2022 to June 2023. All the patients who had culture-proven typhoid were included in the study. Antibiotic sensitivity was determined against conventional and latest antibiotics used for typhoid fever. Data was analyzed through SPSS24.
Results: Out of 284 patients, 60.6% (n=172) were males and the mean age was 24.07±11.65 years. Only 11.3% (n=32) had non-resistant typhoid fever. Extended Spectrum Beta lactamase resistance was noted in 43.3 % (n=123), Extensive drug resistance (XDR) in 37.3% (n=106), and multidrug resistance (MDR) in 8.1% (n=23) of total cases. Salmonella typhi was sensitive to Azithromycin and Meropenem in 100% and 99.6% of cases respectively. Its sensitivity to cotrimoxazole, Chloramphenicol, and Ampicillin was 48.9%, 17.6%, and 7.70% respectively. Only 2.5% of typhoid cases were sensitive to Ciprofloxacin.
Conclusion: Drug-resistant typhoid has shown a rising trend. Conventional antibiotic therapy has developed significant resistance. Azithromycin and Meropenem have shown good sensitivity to Salmonella.
Keywords: Drug Resistance, Sensitivity, Typhoid
Additional Files
Published
How to Cite
Issue
Section
License
Copyright (c) 2023 The authors retain the copyrights. Authors are permitted and encouraged to post their work online (e.g. in institutional repositories or on their website), as it can lead to productive exchanges, as well as greater citation of published work.
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Readers may “Share-copy and redistribute the material in any medium or format” and “Adapt-remix, transform, and build upon the material”. The readers must give appropriate credit to the source of the material and indicate if changes were made to the material. Readers may not use the material for commercial purpose. The readers may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
